A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers

Inclusion Criteria: 1. Male or female aged 50 to 80 2. Body mass index 17.5 to \< 35 kg/m2, inclusive at the time of screening 3. Mini-Mental State Score of ≥ 25 points at screening 4. Must provide written informed consent Exclusion Criteria: 1. Abnormalities in vital signs at screening or baseline 2. Clinically significant abnormal hematology or biochemistry values, as determined by the investigator at screening and/or baseline. 3. Previous clinically significant systemic illness or infection within the past 4 weeks prior to screening or baseline, as determined by the investigator 4. Clinically significant ECG abnormalities 5. Use of tobacco- or nicotine-containing products in the past month or unwillingness to abstain during study participation 6. Participation in another clinical study of a drug or device 7. Known allergy to the study drug (Xanamem®) or any of the excipients 8. Subjects who are likely to be unable to comply with the study schedule and/ or subjects with an inability to communicate well with the investigator 9. Positive testing for human immunodeficiency virus (HIV), hepatitis B surface antigen, or hepatitis C antibodies at screening 10. Subjects with a history of drug abuse or addiction in the past 5 years. 11. Evidence of alcohol abuse (defined as greater than 21 standard units per week for males and greater than 14 standard units per week for females)